Am J Health Syst Pharm. 2006;63(24):2466-2472. The rationale for the lack of clinically relevant weight gain with insulin detemir therapy has not yet been established. It may be attributed to ...

Levemir (insulin detemir) has a shorter duration of action than other long-acting basal insulins like Sanofi's Lantus (insulin glargine) and biosimilars and Novo Nordisk's newer product Tresiba ...

Use of the long-acting insulin analogs glargine and detemir does not reduce the risk of diabetic ketoacidosis in children and adolescents with type 1 diabetes mellitus (T1DM), compared with the ...

Ruby Smart, 15, has been taking Levemir (detemir) insulin since she was diagnosed with type 1 diabetes more than two years ...

a DB = double-blind, DM = diabetes mellitus, HbA 1c = glycosylated hemoglobin, MC = multicenter, NPH = isophane insulin human, NR = not recorded, OL = open-label, PG = parallel-group, R = randomized.